Tookad (padeliporfin) / Steba Biotech  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tookad (padeliporfin) / ImPact Biotech
2020-004494-41: This is a study that will evaluate the safety and efficacy of TOOKAD® (padeliporfin) Vascular Targeted Photodynamic Therapy (VTP) in the Treatment of Low Grade Upper Tract Urothelial Cancer (UTUC).

Not yet recruiting
3
100
Europe
TOOKAD®, [PRD5572518], Powder for solution for injection, TOOKAD®
Steba Biotech S.A., STEBA BIOTECH S.A., Steba biotech, S.A., Steba Biotech, S.A., Steba Biotech S.A., Steba Biotech, S.A., Steba biotech, S.A.
Low Grade Upper Tract Urothelial Cancer, Urinary tract cancers, Diseases [C] - Cancer [C04]
 
 
ENLIGHTED, NCT04620239: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer () Study

Recruiting
3
100
Europe, US, RoW
padeliporfin VTP, WST11
Steba Biotech S.A., PrimeVigilance, ICON plc
Transitional Cell Cancer of Renal Pelvis and Ureter
12/24
01/29

Download Options